Cell line development market share,size,trends (2016-2023

Cell line development market is gaining massive business space in the industry due to the growing demand for biosimilars, novel drugs, and vaccines in the biotechnology industry. “Cell culture can be defined as the process by which cells are grown under controlled conditions, generally outside of their natural environment.” The development in research activities due to rising prevalence of cancer and auto immune disorders will create more need for cell lines, in turn fueling the global cell line development industry. According to Global Market Insights, Inc., “Cell Line Development Market size is anticipated to grow at a CAGR of 13% over the period of 2016-2023.” In addition to this, favorable government initiatives to improve healthcare set-up and the development of advanced technologies will subsequently surge the cell line development industry trends over the coming years.

This industry is analyzed based on products, source, cell line, geography, and applications. The cell line development market by product is segmented into three main types namely, reagents & media, equipment, and accessories & consumables. Reagents and media market share pegged at USD 1.5 billion in 2015 will continue to be the major product in the coming six years. Reagents & media are used in procedures including drug discovery, toxicity testing, regenerative medicines, and tissue engineering. Increasing usage of reagents & media in these measures will strengthen the product demand. Accessories and consumables market is likely to observe the highest annual growth rate of 16.3% from 2016-2023. The increasing usage rate of disposables in monoclonal antibodies and vaccines will in turn boost the cell line development industry. Equipment product segment is estimated to surpass USD 3 billion by 2023. This product segment accounted for 41.4% market share in 2015, and is expected to lose ground to the accessories and consumables market over the coming years.

Request Sample Copy of this Report @ https://www.gminsights.com/request-sample/detail/429

Mammalian and non-mammalian are the two types of sources in the cell line development industry. Within this, the non-mammalian is further classified into insects and amphibians. Mammalian cell line development dominated the market share in 2015 and is expected to exhibit similar trends, driven by the improved engineering and expression systems. Furthermore, the non-mammalian source market accounted for 25% of the industry share in 2015.

Based on cell line; recombinant, primary cell line, hybridomas, and continuous cell line are the four types in the cell line development industry. Among the four, recombinant cell line development market attained the highest industry share in 2015. Over the coming years, this market is probable to lose industry share to the hybridomas and primary cell line segments. Hybridoma cells accounted for the second highest market share in 2015. These cells are grown at larger density in culture flasks and roller bottles. Growing hybridoma cells culture, which can produce high density cultures over 15 to 25 times will in turn fuel the global cell line development industry growth.

Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/429

Considering the global trends, North America led the global cell line development industry, owing to enhanced healthcare infrastructure, rinsing awareness regarding cell therapy, and increasing demand for biologics in the U.S. The U.S. cell line development market is projected to account for 85% market share over the period of 2016-2023.

Asia Pacific cell line development market is witnessing a significant growth due to existence of developing healthcare infrastructure, favorable government policies, rapid economic development. Significant investments by the global companies, mainly in India and China, will flourish the regional growth.

Latin America cell line development market is foreseen to register a CAGR of 13.3% over the period of 2016-2023. Brazil is another emerging market witnessing healthy growth in the cell line development industry.

Tissue engineering, research, drug discovery, bioproduction, and toxicity testing are the key application segments in the cell line development industry. Bioproduction application occupied the highest market value of USD 1306 million, shadowed by toxicity testing application market worth USD 598.3 million in 2015. The bioproduction is the leading application which is estimated to surpass USD 3 billion by 2023. The presence of advanced processes, introduction of biosimilars, and increase in R&D activities are the attributing factors in augmenting the overall segment growth.

The industry will witness intense competition and strategic initiatives to sustain the market position. The market is dominated by a limited number of players with better financial muscle thus providing threat to the new entrants in the industry. Notable companies operating in cell line development industry are Selexis American Type Culture Collection (ATCC), Thermo Fisher Scientific, GE Healthcare, Lonza Group, WuXi AppTec, European Collection of Cell Cultures (ECACC), Sigma-Aldrich Corporation, Sartorious, and Corning.

About Global Market Insights

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: https://www.gminsights.com
Blog: https://gminsights.wordpress.com

This release was published on openPR.